Mobile website
Antitumor Responses Induced by Recombinant Vaccinia Viruses Expressing p53 and B7
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
This study was aimed to explore antitumorresponses induced by recombinant vaccinia viruses expressing a point mutant p53 (rVV-p53FL) and enhancive effects of recombinant vaccinia viruses expressing costimulatory molecule B7 (rVV-B7). Methods: A 135 Cys to Tyr point mutant p53 protein was used as the model of tumor associated antigen. rVV-p53FL and rVV-B7 were used as vaccines to test their induction of CTLs and antitumor immunity. Results: Immunization BABL/c mice with rVV-p53FL could elicited specific CD8 + CTLs that could effecively lyse P815-mp53 cells, a transfectant of the murine P815 mastocytoma containing the mutant p53 gene. Treatment with rVV-p53FL could survive a part of mice challenged with 1×10 6 P815-mp53. Treatment with rVV-p53FL could significantly prolong survival of tumor-bearing mice. Admixture at 1∶1 ratio of rVV-p53FL and rVV-B7 could enhance therapeutic antitumor effects of rVV-p53FL. Conclusion: Mutant P53 over-expressed in tumor cells can render cells targets for specific CTLs generated by immunization with mutant P53 protein based vaccine. Costimulatory molecule B7 can enhance tumor-associated antigen inducing antitumor responses.
Keywords:
Project Supported:
Clc Number:
